Cancer & SURVIVEiT News
Category Filter:
FDA approves pembrolizumab for advanced endometrial carcinoma
FDA approves pembrolizumab for advanced endometrial carcinoma On March 21, 2022, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck), as a single agent, for patients with advanced endometrial carcinoma…
FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer
FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer On April 22, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients…
Financial Advocacy Program For Gynecologic Cancer Patients
Cancer doesn’t care what your financial situation is. Thankfully, Carol’s Wish does. Going through cancer treatments is a strenuous time for any cancer patient. It is tough both mentally and…
FDA approves combo KEYTRUDA + LENVIMA for some endometrial carcinoma patients
On September 17, 2019, the Food and Drug Administration granted accelerated approval to the combination of pembrolizumab (KEYTRUDA, Merck) plus lenvatinib (LENVIMA, Eisai) for the treatment of patients with advanced…